We provide you with 20 years of free, institutional-grade data for GLTO stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of GLTO. Explore the full financial landscape of GLTO stock.
| Reported Date | CIK | Ticker | Type |
|---|
Galecto, Inc(NASDAQ:GLTO) 
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of sever...
Website: http://www.galecto.com
Founded: 2011
Full Time Employees: 23
CEO: Hans Thalsgård Schambye
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about GLTO stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.